{"entity":{"id":"nct06499285","kind":"trial","name":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","aka":["RENEW"],"tldr":"A phase 3 trial of Elritercept run by Takeda, now recruiting.","summary":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions is a phase 3 interventional study registered as NCT06499285 by Takeda, with 225 participants planned, started 2025-05-06. Conditions listed: Myelodysplastic Syndromes. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06499285","url":"https://clinicaltrials.gov/study/NCT06499285"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mds","mds-lower-risk"],"sections":[],"technologies":["cytokine-therapy"],"targets":[],"drugs":["elritercept"],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06499285","phase":"3","setting":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)","sponsor":"Takeda","participation":[{"nct":"NCT06499285","source":"https://clinicaltrials.gov/study/NCT06499285","fetchedAt":"2026-10-07T16:54:43.174Z","studySha256":"ef2acaddf7b13aab4198f33c525cb2c3d2163c66c095763b970d0088c88194b2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-21","leadSponsor":"Takeda","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":225,"enrolmentType":"ESTIMATED","siteCount":177,"recruitingSiteCount":138,"countries":["Australia","Brazil","Bulgaria","Canada","Chile","Czechia","France","Germany","Hungary","India","Ireland","Israel","Italy","Lithuania","Peru","Poland","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-05-06","startedType":"actual","enrolled":225,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06499285/","neighbours":{"cancer":[{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"}],"drug":[{"id":"elritercept","kind":"drug","name":"Elritercept","route":"/drugs/elritercept/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}]}}